BioSpace News Archive

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2023, on Thursday, December 15, 2022, at 10:30 am Eastern Time.

Neuronetics, Inc. is named a 2022 bronze winner by the Merit Awards for Healthcare in the HealthTech Patient Care category for its NeuroStar Advanced Therapy.

ENDRA Life Sciences Inc. announced today that it will be effecting a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will host a webcast to discuss the updated results from the Phase 1 open-label, dose-escalation study evaluating selinexor in combination with ruxolitinib in patients with treatment-naïve myelofibrosis at the 64th American Society of Hematology (ASH) 2022 Annual Meeting and Exposition.

BioAge Labs, Inc. (“BioAge”), a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced positive Phase 1b clinical data for BGE-105, a highly selective, potent, orally available small-molecule agonist of the apelin receptor APJ.

Hexaell Biotech Co., Ltd announced that the China National Medical Products Administration has cleared the IND, enabling the company to proceed a clinical trial for HepaCure, a novel device-drug combination product using hiHeps technology, a cell transdifferentiation technology which could directly convert human fibroblasts to hepatocyte like cells with liver cell functions.

BioPorto A/S announced that Mr. Nis Kruse joined the Company as EVP of Strategic Partnerships and General Manager of EMEA & APAC.

AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that this week the Proceedings of the National Academy of Sciences (PNAS) will publish results of a groundbreaking study demonstrating a customized, synthetic peptide’s ability to selectively detect Alzheimer’s disease.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 21 newly-hired employees stock options to purchase an aggregate of 134,600 shares, and restricted stock units covering an aggregate of 67,300 shares, of BioCryst common stock.

Journey Medical Corporation (“Journey Medical” or “Company”) (Nasdaq: DERM) today announced that members of Journey Medical’s management team will participate in the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference, which is being held on Thursday, December 8, 2022 in Miami, FL.